Neurocrine Biosciences' INGREZZA Shows Promising Results for Tardive Dyskinesia Treatment

Neurocrine Biosciences Advances Treatment for Tardive Dyskinesia with New Findings

Neurocrine Biosciences, Inc. announces pivotal findings from a post-hoc analysis of its Phase 4 KINECT-PRO™ study, showcasing the effectiveness of its once-daily medication, INGREZZA® (valbenazine), in treating tardive dyskinesia (TD). Presented at Psych Congress 2025, the analysis reveals that an impressive 57.8% of participants achieve symptomatic remission by Week 24. Notably, the remission rates vary depending on the dosage, with 58.3% of patients responding positively at 40 mg, 44.4% at 60 mg, and 62.5% at 80 mg. This study defines remission as an Abnormal Involuntary Movement Scale (AIMS) score of ≤1 for each body region, highlighting the efficacy of INGREZZA in alleviating the involuntary movements characteristic of TD.

The findings from the KINECT-PRO analysis not only demonstrate the potential for quicker symptomatic remission but also underscore the medication's impact on patient-reported outcomes (PROs). Patients who achieve remission report significant improvements across several metrics, including the Tardive Dyskinesia Impact Scale (TDIS™), the Sheehan Disability Scale (SDS), and the EuroQoL Visual Analog Scale (EQ-VAS). These enhancements reflect substantial gains in physical, social, and emotional well-being, offering hope for those struggling with the debilitating effects of TD. Sanjay Keswani, M.D., Chief Medical Officer at Neurocrine Biosciences, emphasizes that these results affirm the importance of targeting symptomatic remission in treatment protocols.

As Neurocrine continues to innovate within the biopharmaceutical landscape, the implications of the KINECT-PRO findings are significant. They not only advance the understanding of TD treatment options but also position Neurocrine as a key player in addressing neurological disorders. The ongoing commitment to research and development in this area may inspire further investment and interest from stakeholders, especially amid the mixed sentiments from analysts regarding the company's future. The KINECT-PRO study stands as a testament to Neurocrine's dedication to improving patient outcomes and advancing therapeutic solutions for challenging medical conditions.

In addition to these promising results, analysts have varied opinions on Neurocrine's market potential, reflecting broader uncertainties within the healthcare sector. Factors such as regulatory approvals, competition, and clinical trial outcomes continue to shape the landscape for biopharmaceutical companies. As Neurocrine navigates these challenges, the insights from the KINECT-PRO analysis may serve as a critical touchpoint for evaluating the company's strategic direction and market viability.

Overall, Neurocrine's advancements in treating tardive dyskinesia through INGREZZA not only showcase its commitment to patient health but also highlight the evolving dynamics of the biopharmaceutical industry. As the company forges ahead, the findings could play a significant role in shaping future treatment paradigms for neurological disorders.